CVS Health에 대한 매도 수량은 투자자에게 CVS Health의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

CVS Health (NYSE:CVS) 주식, 공매도 수량 보고

CVS HEALTH CORP

CVS Health

CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.

S&P 500

Analyst Color

AAPL

AMZN

BKNG

GOOGL

MSFT

NVDA

NWSA

TSLA

S&amp;P 500 지수 상장 기업 중 거의 80%가 2025년 1분기에 수익 전망치를 상회했다. 이에 S&amp;P 500 지수는 13.3%의 수익 급등을 기록하며 2분기 연속 두 자릿수 퍼센트 성장률을 기록했다.

S&amp;P 500 1분기 이익 성장률, 광범위한 호실적 속 2분기 연속 두 자릿수 퍼센트 성장 기록

Shibuya,,Tokyo,,Japan,-,March,5,2022:,Exterior,Of,The

Long Ideas

Tech

Trading Ideas

PLTR

UBER

VRSN

2024년 S&amp;P 500 지수 순위표에는 의외의 이름과 익숙한 강자들이 포함되어 있다. 대형주 팔란티어 테크놀로지스(NASDAQ:PLTR)가 연초 대비 64% 급등하며 캐시 우드의 아크 인베스트 유니버스에서 유일하게 S&amp;P 500의 최고 수익률 목록에 이름을 올린 종목이다.

팔란티어: S&amp;P 500 급등주 중 캐시 우드가 선택한 유일한 종목

Health,Care,Billing,Statement,With,Stethoscope,,Bottle,Of,Medicine,For

Government

Large Cap

News

Regulations

Health Care

After-Hours Center

Movers

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

유나이티드헬스 그룹(NYSE:UNH), 엘리반스 헬스(NYSE:ELV) 및 CVS 헬스(NYSE:CVS) 등 헬스케어 주식은 메디케어 및 메디케이드 서비스 센터 (CMS)가 메디케어 어드밴티지 (MA) 플랜에 대한 감사를 크게 확대한다고 발표 한 후 수요일 애프터마켓에서 급락했따.

유나이티드헬스·CVS헬스 등 헬스케어 주식 하락한 이유는?

CVS Health Corp

Morgan Stanley ETF Trust Calvert Ultra-Short Investment Grade ETF

CARDIOVASCULAR SCI INC by Cardiovascular Sciences, Inc.

Morgan Stanley ETF Trust Calvert US Select Equity ETF

CVS Group PLC

CIVITAS SOCIAL HSG PLC by CIVITAS SOCIAL HSG PLC

CV Sciences Inc

COVISTA COMMUNS INC by Covista Communications, Inc,

Covista Communications Inc

CONVERGENCE SYS INC CL A by Convergence Systems Inc.

Convergence Systems Inc

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics</a>

CLOV

EHTH

ELEV

GOCO

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill'- Bloomberg

<a href="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true" title="https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-05/medicare-surfaces-as-target-for-cuts-to-pay-for-trump-tax-bill?srnd=phx-politics&amp;embedded-checkout=true</a>

'Medicare Surfaces as Target for Cuts to Pay for Trump Tax Bill' -Bloomberg

Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) signaled support for reforms that would curb industry billing practices that have led to billions <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">in additional payments</a>.
What Happened: Last fall, Senators Mike Crapo and Ron Wyden asked insurers for ideas to address home-visit-related payment practices. 
Human, one of the largest Medicare Advantage insurers in the U.S., recently shared its stance. In a one-page policy overview viewed by The Wall Street Journal, the company favored limiting insurers&#8217; use of home visit diagnoses to obtain higher payments.
These home visits, often conducted by nurse practitioners and not directly linked to treatment, have become increasingly scrutinized for their role in boosting payments by identifying sometimes questionable or unverified medical conditions.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45775858/unitedhealth-board-reelects-directors-hikes-dividend-as-ceo-pledges-review-of-medicare-practices" rel="noreferrer noopener">UnitedHealth Board Reelects Directors, Hikes Dividend As CEO Pledges Review Of Medicare Practices</a>
Why It Matters: Humana&#8217;s position is a notable shift in the ongoing debate over payments tied to diagnosis coding in the $460 billion Medicare Advantage program.
A Wall Street Journal investigation <a target="_blank" href="https://www.wsj.com/health/healthcare/medicare-billing-changes-humana-6f20c05b" rel="noreferrer noopener">revealed</a> that such home-based assessments generated $15 billion in <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/45108509/humana-does-not-alter-2025-outlook-despite-sales-miss-and-medicare-membership-decline" rel="noreferrer noopener">additional revenue for Medicare</a> Advantage insurers between 2019 and 2021.
UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) accounted for roughly two-thirds of those payments, with an average gain of $2,735 per home visit. Humana&#8217;s average was $1,525.
UnitedHealth&#8217;s HouseCalls program conducted around 2.9 million home visits last year, while CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), through Signify Health, also operates a similar model.
Insurers argue that many of these home visits help detect undiagnosed conditions. However, reports indicate that diagnoses are frequently recorded by nurses who aren&#8217;t treating the conditions and may rely on broad training to spot potential health issues.
These diagnoses often don&#8217;t align with those documented by the patients&#8217; primary care physicians.
Humana has proposed that insurers should only receive extra payments for diagnoses made during home visits if those conditions are documented during other types of medical encounters, such as health-risk assessments outside the home or standard clinic visits.
The company also recommends limiting another controversial practice: diagnosis coding from medical chart reviews unrelated to specific patient visits. Humana&#8217;s policy update comes after an internal review launched by CEO Jim Rechtin, who took the helm in July 2023.
Meanwhile, Medicare&#8217;s top official, Mehmet Oz, has committed to tightening oversight of the Advantage program.
Legal Issues: In May, the U.S. Department of Justice filed a lawsuit against <a href="https://www.benzinga.com/general/health-care/25/04/44927473/despite-medicaid-pressure-elevance-health-delivers-strong-q1-performance-reiterates-profit-outlook" target="_blank" rel="noreferrer noopener">Elevance Health, Inc.</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>), Humana, and Aetna, Inc. 
The lawsuit alleges that from 2016 through at least 2021, the insurers paid hundreds of millions of dollars in illegal kickbacks to brokers in exchange for enrolling Medicare beneficiaries into their <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45202124/humana-elevance-aetna-face-doj-lawsuit-over-illegal-kickback-scheme-discrimination-against-disabled-people" rel="noreferrer noopener">Medicare Advantage plans</a>.
And in February, the Justice Department launched a civil fraud investigation into UnitedHealth&#8217;s <a href="https://www.benzinga.com/25/02/43879859/doj-investigates-unitedhealth-probe-accuses-of-inflating-medicare-diagnoses" target="_blank" rel="noreferrer noopener">Medicare billing practices</a>.
The probe examines UnitedHealth's Medicare Advantage plans and physician groups following reports that the company received billions in federal payments for questionable diagnoses.
Price Action: HUM stock is up 0.29% at $231.88 at the last check on Thursday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/45791411/procter-gamble-to-eliminate-7000-roles-divest-brands-in-new-restructuring-strategy" target="_blank" rel="noreferrer noopener">Procter &amp; Gamble To Eliminate 7,000 Roles, Divest Brands In New Restructuring Strategy</a></li>
</ul>
Image: Shutterstock

Humana Backs Reforms To Limit Medicare Advantage Billing Practices

Nearly 80% of S&amp;P 500 companies exceeded earnings forecasts in the first quarter of 2025, helping the index post a 13.3% profit surge — its second straight quarter <a href="https://www.benzinga.com/earnings">of double-digit growth.</a>
According to the latest Earnings Insight report from FactSet, authored by vice president and senior earnings analyst John Butters, only 18% fell short of analyst forecasts.
About 98% of S&amp;P 500 companies now have reported first-quarter results. And up to 78% beat earnings-per-share (EPS) expectations—a figure that outpaces both the 5-year average of 77% and the 10-year average of 75%. 
&#8220;In aggregate, companies are reporting earnings that are 8.2% above expectations. This surprise percentage is above the 1-year average (+6.1%), below the 5-year average (+8.8%), and above the 10-year average (+6.9%),&#8221; Butters wrote. 
The "Magnificent Seven" — Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>), Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>), and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) — outperformed the broader index.
Six of the seven companies beat EPS estimates (86%), with an average earnings surprise of 14.9%, nearly twice the S&amp;P 500 average.
See Also: <a href="https://www.benzinga.com/25/05/45517783/magnificent-7-stun-the-street-with-the-best-earnings-beat-since-2021">Magnificent 7 Stun The Street With Best Earnings Beat Since 2021</a>
<h3 class="wp-block-heading">Which Sectors Led The Upside?</h3>
Health Care topped the leaderboard with 92% of its constituents beating estimates, followed by Communication Services (87%) and Information Technology (86%). 
At the opposite end, Utilities and Energy sectors posted the weakest beat rates at 61% and 64%, respectively.
Communication Services delivered the strongest upside surprises, boasting an average earnings surprise of +23.8%. 
Meta Platforms Inc. beat by over $1 per share ($6.43 vs. $5.23), while Alphabet Inc. posted EPS of $2.81 against estimates of $2.02. 
Other strong performers included Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Interpublic Group of Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>), News Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>), and Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>).
Consumer Discretionary followed with a 9.4% surprise rate. Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) surged past expectations with $24.81 in EPS vs. $17.37 forecast, while NIKE Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) posted $0.54 vs. $0.30.
Health Care delivered an 8.6% surprise, with Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) earning $0.92 per share vs. $0.67 estimate, and CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) reporting $2.25 vs. $1.70. The sector also had the highest beat rate, with 92% of companies exceeding EPS forecasts.
<h3 class="wp-block-heading">Market Response: Positive Earnings Are Paying Off</h3>
Investors rewarded strong results. Companies that beat expectations saw their stock prices rise by an average of 1.9% from two days before to two days after earnings — the highest average gain since the third quarter of 2022. 
Conversely, companies that missed expectations saw a more muted decline of -1.9%, smaller than the 5-year average drop of -2.3%.
<h3 class="wp-block-heading">Valuations Are Getting Stretched</h3>
The forward 12-month price-to-earnings (P/E) ratio for the S&amp;P 500 rose to 21.3, above the 5-year average of 19.9 and the 10-year average of 18.4. 
That increase reflects a 5.4% rise in the index since March 31, while forward EPS estimates have slipped less than 0.1%.
By sector, Consumer Discretionary (28.1) and Information Technology (27.2) have the richest valuations, while Energy (14.6) trades at the lowest. 
The trailing 12-month P/E ratio also moved higher to 25.9, above the historical 5- and 10-year norms.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45722678/magnificent-seven-closed-a-blockbuster-may-added-nearly-2-trillion-in-market-value">Magnificent Seven Closed A Blockbuster May, Added Nearly $2 Trillion In Market Value</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgb(59 130 246/0.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Image: Shutterstock

S&P 500 Q1 Earnings Stun Wall Street Again With Broad-Based Beats, Double-Digit Growth

Amazon Pharmacy has announced two updates to make medication management easier and more accessible for millions of customers across the U.S., especially caregivers <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">and Medicare patients</a>.
The enhancements include a new caregiver feature and expanded access to its PillPack service for Medicare beneficiaries.
The caregiver support <a target="_blank" href="https://www.aboutamazon.com/news/retail/amazon-pharmacy-caregiver-medicare-pillpack" rel="noreferrer noopener">feature</a> allows Amazon Pharmacy customers to invite trusted individuals to manage medications on their behalf.
Once verified, caregivers can oversee prescriptions through their own Amazon accounts.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45748544/walmart-leverages-automation-and-ai-to-cut-costs-and-grow-paving-the-way-for-other-retailers-report" rel="noreferrer noopener">Walmart Leverages Automation And AI To Cut Costs And Grow, Paving The Way For Other Retailers: Report</a>
According to AARP, this update addresses a growing need: One in five U.S. adults, or about 53 million people, cares for an aging family member. Many spend the equivalent of a full workday each month coordinating health care, with medication management being among the most complex tasks.
Setting up caregiver access is simple: A customer logs into their Amazon Pharmacy account and sends an invitation via mobile phone number. After verifying a few details, like the customer&#8217;s date of birth, the caregiver receives a secure link by text message and can begin managing prescriptions from their account.
In addition, Amazon Pharmacy has expanded access to its PillPack service for Medicare Part D members.
PillPack offers personalized medication packets organized by date and time, designed to simplify the daily routine of people taking multiple prescriptions.
This service is now available to over 50 million Medicare Part D beneficiaries, helping eliminate the burden of sorting pills and tracking refill schedules. Eligible customers can sign up through their Amazon Pharmacy account to enroll.
Customers will receive monthly pre-sorted packet shipments after reviewing their medications and insurance details. Amazon coordinates all refills so medications arrive together each month.
Amazon Pharmacy offers one-time prescriptions and ongoing medication needs through the Amazon app.
The platform provides delivery updates via text or email and offers Prime members in select cities—including New York City, Los Angeles, and Seattle—free same-day delivery.
The pharmacy accepts most major insurance plans, including Medicare Part D nationwide and Medicaid in select states.
Prime members benefit from additional savings through RxPass and other Prime-exclusive discounts, with potential savings of up to 80% on thousands of medications when paying without insurance.
PillPack services are free and include 24/7 access to pharmacists and monthly medication deliveries.
Amazon bought PillPack seven years ago for over $750 million, but it still hasn&#8217;t revealed how much money its Amazon Pharmacy business is making in its quarterly earnings.
According to Forbes, <a href="https://www.forbes.com/sites/brucejapsen/2025/06/03/amazon-a-tiny-pharmacy-player-seeks-to-dent-cvs-and-walgreens-medicare-share/" target="_blank" rel="noreferrer noopener">studies</a> show that CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) owned Walgreens control about 40% of the U.S. prescription drug market combined, while Amazon holds less than 1%. CVS and Walgreens do not share how many Medicare Part D prescriptions they fill.
Now, Amazon Pharmacy is adding features aimed at seniors to break into the fast-growing Medicare market, as more than 11,000 Americans turn 65 daily.
Most recently, Talkspace (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TALK#NASDAQ">TALK</a>), an online behavioral health company, collaborated with Amazon Pharmacy to simplify the pharmacy experience for Talkspace members and streamline medication management and adherence support for providers.
Talkspace members can <a target="_blank" href="https://www.businesswire.com/news/home/20250529796020/en/Talkspace-Becomes-First-Behavioral-Health-Provider-to-Integrate-with-Amazon-Pharmacy-Offering-Psychiatry-Services-and-a-More-Seamless-Medication-Management-Experience" rel="noreferrer noopener">fulfill</a> prescriptions from their Talkspace provider through Amazon Pharmacy.
Price Action: AMZN stock is up 0.49% at $207.67 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45745834/nio-stock-drops-after-q1-results-and-outlook-disappoints-the-street-margins-shrink" target="_blank" rel="noreferrer noopener">Nio Stock Drops After Q1 Results And Outlook Disappoints The Street, Margins Shrink</a></li>
</ul>
Photo by MACH Photos via Shutterstock

TALK

Amazon Pharmacy Challenges CVS Health And Walgreens Dominance, Unveils New Features To Expand Medicare Access

<a href="https://x.com/AnjKhem/status/1929915330773590434" title="https://x.com/AnjKhem/status/1929915330773590434">https://x.com/AnjKhem/status/1929915330773590434</a>

Yahoo Finance Senior Health Reporter Anjalee Khemlani Posts On X "EXCLUSIVE: CVS commits to $20B over 10 yrs to modernize healthcare experience. ..."

Ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $78.4, a high estimate of $84.00, and a low estimate of $71.00. Surpassing the previous average price target of $72.30, the current average has increased by 8.44%.
<img src="https://www.benzinga.com/files/images/story/2025/1748887249_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive CVS Health. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$79.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$84.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$81.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$82.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Michael Ha</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Ann Hynes</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$76.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CVS Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for CVS Health's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CVS Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>All You Need to Know About CVS Health</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>CVS Health: Financial Performance Dissected</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: CVS Health's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 6.96%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CVS Health's net margin is impressive, surpassing industry averages. With a net margin of 1.88%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): CVS Health's ROE stands out, surpassing industry averages. With an impressive ROE of 2.33%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.7%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.06, CVS Health faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 10 Analyst Ratings Have To Say About CVS Health

Barclays analyst Andrew Mok maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $82 to $79.

Price Target

Barclays Maintains Overweight on CVS Health, Lowers Price Target to $79

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has fallen 3.08% since its last report. The company recently reported that it has 15.90 million shares sold short, which is 1.26% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.23 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748444419_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 9.70%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About CVS Health?

The <a href="https://www.benzinga.com/topic/s-p-500">S&amp;P 500's leaderboard</a> for 2024 features some surprising names and familiar heavyweights. At the top sits NRG Energy Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRG#NYSE">NRG</a>), scorching ahead with over 70% gain year-to-date, fueled by a rally in power demand and clean energy transitions. 
Hot on its heels is heavyweight Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), posting a strong 64% YTD surge, making it the only stock from Cathie Wood's ARK Invest universe to crack the S&amp;P 500's top-performing <a href="https://finviz.com/screener.ashx?v=141&amp;f=idx_sp500&amp;o=-perfytd">list</a>.
Other solid performers include Howmet Aerospace Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) (+49% YTD), Philip Morris International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) (+47%) and Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) (+38%), showing strength across energy, industrials, consumer staples, and tech-driven services. Not to be overlooked, General Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GE#NYSE">GE</a>) and GE Vernova Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) both shine with gains near 37%, while CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and VeriSign, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRSN#NASDAQ">VRSN</a>) round out a diverse group climbing the ranks.
Read Also: <a href="https://www.benzinga.com/general/space/25/05/45584539/donald-trumps-175-billion-golden-dome-could-trigger-a-new-space-arms-race-expert-warns-its-opening-a-pandoras-box">Donald Trump&#8217;s $175 Billion Golden Dome Could Trigger A New Space Arms Race, Expert Warns: &#8216;&#8230;It&#8217;s Opening A Pandora&#8217;s Box&#8217;</a>
Amid this broad mix, Palantir stands out &#8211; not just for its impressive gains but because it's the lone representative from Cathie Wood's innovation-driven ARK funds that's making waves among America's blue-chip giants. After a spectacular 485% surge over the past year, Palantir stock has captured investor attention with its cutting-edge data analytics and government contracts.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0526"><img loading="lazy" decoding="async" width="631" height="486" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26073639/Screenshot-2025-05-26-at-5.06.19-PM.png" alt="" class="wp-image-927473" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26073639/Screenshot-2025-05-26-at-5.06.19-PM.png 631w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/26073639/Screenshot-2025-05-26-at-5.06.19-PM-300x231.png 300w" sizes="(max-width: 631px) 100vw, 631px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0526">Chart created using Benzinga Pro</a>
Technically, Palantir stock remains bullish, trading above its 20-day, 50-day and 200-day moving averages, classic signs that momentum could continue. The MACD (moving average convergence/divergence) indicator and RSI (relative strength index) indicators also support a bullish signal, suggesting Palantir stock's rally isn't finished yet.
However, Wall Street analysts take a more cautious stance. Recent ratings from New Street Research, Goldman Sachs, and Deutsche Bank average to a price target near $118 &#8211; only marginally above the current $123 price &#8211; implying limited upside for Palantir stock.
For Cathie Wood's ARK funds, Palantir remains the rare success story in the S&amp;P 500 this year, proving that selective innovation still has a place amid the index's top performers.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45603240/trump-agrees-to-extend-50-tariffs-on-europe-until-july-9-it-was-my-privilege-to-do-so">Trump Agrees To Extend 50% Tariffs On Europe Until July 9: &#8216;It Was My Privilege To Do So&#8217;</a></li>
</ul>
Image: Shutterstock/Hiroshi-Mori-Stock

Palantir: The Only Cathie Wood Pick Among S&P 500's Top Performers

Benzinga examined the prospects for<a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener"> many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
U.S. markets experienced heightened volatility this week as President Donald Trump intensified trade tensions by threatening a 25% tariff on foreign-made Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) products and announcing a 50% tariff on European Union imports starting June 1. These announcements led to a decline in major indices, with the S&amp;P 500 falling 0.7%, the Dow Jones dropping 0.6%, and the Nasdaq decreasing by 1%. Apple shares were particularly affected, losing 3% in value.
Investor concerns over the U.S. fiscal outlook grew as the 30-year Treasury yield briefly surpassed 5.15%, reflecting apprehensions about rising deficits and debt sustainability. A weak 20-year Treasury auction further exacerbated these fears, indicating diminished demand for long-term U.S. debt.
Looking ahead, market participants are closely monitoring upcoming U.S.-China trade negotiations and potential adjustments to existing tariffs. The Federal Reserve's stance on interest rates remains a focal point, especially as real borrowing costs rise, tightening broader financial conditions. Additionally, corporate earnings reports and economic indicators will continue to influence market dynamics in the coming weeks.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/trading-ideas/technicals/25/05/45544614/google-could-smart-glasses-smart-speech-spark-the-stocks-next-big-leap">"Google: Could smart glasses, speech spark the stock's next big leap?"</a>, by Surbhi Jain, reports that Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) is gaining investor attention as its partnership with Warby Parker to develop AI-powered smart glasses and advancements in speech recognition technology signal a potential new growth narrative beyond search.
<a href="https://www.benzinga.com/government/regulations/25/05/45574763/goldman-sachs-defense-stock-golden-dome">"Goldman Sachs: Golden Dome is big win for this defense stock"</a>, by Piero Cingari, reports that Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) analyst Noah Poponak reiterated a Buy rating on L3Harris Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>), highlighting its potential to secure billions in contracts from the Trump administration's $175 billion "Golden Dome" missile defense initiative.
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45531583/amd-nvidia-shares-jump-after-musk-highlights-xais-gpu-needs-we-expect-to-still-buy-a-lot">"AMD, Nvidia shares jump after Musk highlights xAI's GPU needs: ‘We expect to still buy a lot'"</a>, by Adam Eckert, reports that Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose after Elon Musk stated that Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and xAI plan to purchase "a lot" of GPUs from both companies to support AI initiatives like robotaxis and the Optimus robot.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45541780/d-wave-quantum-stock-extends-rally-as-momentum-builds-following-launch-of-new-quantum-system">D-Wave Quantum Stock Extends Rally As Momentum Builds Following Launch Of New Quantum System</a>
<a href="https://www.benzinga.com/25/05/45517783/magnificent-7-stun-the-street-with-the-best-earnings-beat-since-2021">Magnificent 7 Stun The Street With Best Earnings Beat Since 2021</a>
<a href="https://www.benzinga.com/25/05/45540768/medtronic-beats-q4-forecasts-hikes-dividend-plans-diabetes-spinoff">Medtronic Beats Q4 Forecasts, Hikes Dividend, Plans Diabetes Spinoff</a>

The Bears
<a href="https://www.benzinga.com/news/legal/25/05/45568107/solar-energy-stocks-drop-as-house-approves-major-rollback-of-climate-incentives">"Solar energy stocks drop as House approves major rollback of climate incentives"</a>, by Erica Kollmann, reports that Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares fell after the House passed President Trump's "One Big, Beautiful Bill," which rolls back key climate incentives, leaving the solar industry facing uncertainty as the bill moves to the Senate.
<a href="https://www.benzinga.com/25/05/45540759/target-stock-slips-as-q1-earnings-miss-estimates-fy2025-outlook-cut-amid-slowing-sales">"Target stock slips as Q1 earnings miss estimates, FY2025 outlook cut amid slowing sales"</a>, by Nabaparna Bhattacharya, reports that Target Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) shares fell after the company missed Q1 earnings expectations and lowered its FY2025 outlook, citing a 3.8% drop in comparable sales driven by tariffs, weakened consumer sentiment, and backlash from scaling back diversity, equity, and inclusion initiatives.
<a href="https://www.benzinga.com/news/rumors/25/05/45555558/wolfspeed-stock-plunges-59-on-bankruptcy-fears-options-traders-cash-in">"Wolfspeed stock plunges 59% on bankruptcy fears: Options traders cash in"</a>, by Erica Kollmann, reports that Wolfspeed Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares plummeted 59% to $1.28 after reports emerged that the company is preparing to file for Chapter 11 bankruptcy, with options traders profiting from heavy put activity ahead of the news.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/government/regulations/25/05/45554854/health-care-stocks-like-unitedhealth-cvs-tank-on-wednesday-heres-why">Health Care Stocks Like UnitedHealth, CVS Tank On Wednesday: Here's Why</a>
<a href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening">Hims &amp; Hers Health Stock Is Tumbling Thursday: What's Happening?</a>
<a href="https://www.benzinga.com/markets/equities/25/05/45532892/legendary-investor-jeremy-grantham-warns-of-50-stock-market-crash">Legendary Investor Jeremy Grantham Warns Of 50% Stock Market Crash</a>

Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

Markets

Hims & Hers Health, Inc. Class A Common Stock

HIMS

QBTS

WOLF

Benzinga Bulls And Bears: Alphabet, L3Harris, Target — And Latest Tariff News Roils Markets

Whales with a lot of money to spend have taken a noticeably bearish stance on CVS Health.
Looking at options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 62% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $287,031 and 2, calls, for a total amount of $305,444.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $59.0 to $64.0 for CVS Health over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $59.0 to $64.0, over the past month.
<h3>CVS Health 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748026996_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$2.07</td>
<td>$1.76</td>
<td>$1.76</td>
<td>$59.00</td>
<td>$157.3K</td>
<td>87</td>
<td>897</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$1.49</td>
<td>$1.43</td>
<td>$1.48</td>
<td>$60.00</td>
<td>$148.1K</td>
<td>577</td>
<td>1.8K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$0.92</td>
<td>$0.9</td>
<td>$0.92</td>
<td>$59.00</td>
<td>$69.2K</td>
<td>2.4K</td>
<td>4.6K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.75</td>
<td>$2.62</td>
<td>$2.7</td>
<td>$60.00</td>
<td>$54.0K</td>
<td>2.2K</td>
<td>300</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$2.73</td>
<td>$2.59</td>
<td>$2.69</td>
<td>$60.00</td>
<td>$53.8K</td>
<td>2.2K</td>
<td>500</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
Having examined the options trading patterns of CVS Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of CVS Health</h3>
<ul>
<li>Currently trading with a volume of 4,293,678, the CVS's price is up by 0.46%, now at $60.5. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 75 days.</li>
</ul>
<h3>What The Experts Say On CVS Health</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $80.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from RBC Capital has decided to maintain their Outperform rating on CVS Health, which currently sits at a price target of $81. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on CVS Health with a target price of $84. 
&#x2A; Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on CVS Health with a target price of $71. 
&#x2A; An analyst from Barclays has decided to maintain their Overweight rating on CVS Health, which currently sits at a price target of $82. 
&#x2A; Consistent in their evaluation, an analyst from Truist Securities keeps a Buy rating on CVS Health with a target price of $84. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for CVS Health with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

What the Options Market Tells Us About CVS Health

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$59.00</td>
<td>$69.2K</td>
<td>2.4K</td>
<td>4.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$71.00</td>
<td>$39.1K</td>
<td>2.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$200.00</td>
<td>$102.9K</td>
<td>4.0K</td>
<td>920</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$280.00</td>
<td>$99.0K</td>
<td>1</td>
<td>650</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.00</td>
<td>$32.5K</td>
<td>3.5K</td>
<td>279</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$65.00</td>
<td>$38.1K</td>
<td>6.6K</td>
<td>264</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$190.00</td>
<td>$66.9K</td>
<td>25</td>
<td>42</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$36.00</td>
<td>$27.4K</td>
<td>266</td>
<td>38</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 7 day(s) on May 30, 2025. This event was a transfer of 752 contract(s) at a $59.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $69.2K, with a price of $92.0 per contract. There were 2468 open contracts at this strike prior to today, and today 4643 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 1000 contract(s) at a $71.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $39.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4086 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 238 day(s) on January 16, 2026. Parties traded 96 contract(s) at a $200.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $102.9K, with a price of $1075.0 per contract. There were 4074 open contracts at this strike prior to today, and today 920 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option sweep that happens to be bullish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 150 contract(s) at a $280.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $99.0K, with a price of $660.0 per contract. There were 1 open contracts at this strike prior to today, and today 650 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with bearish sentiment. It expires in 602 day(s) on January 15, 2027. Parties traded 250 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $130.0 per contract. There were 3518 open contracts at this strike prior to today, and today 279 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bearish sentiment. It expires in 56 day(s) on July 18, 2025. Parties traded 53 contract(s) at a $65.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $720.0 per contract. There were 6682 open contracts at this strike prior to today, and today 264 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a put option sweep that happens to be bearish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 34 contract(s) at a $190.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $66.9K, with a price of $1970.0 per contract. There were 25 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 15 contract(s) at a $36.00 strike. The total cost received by the writing party (or parties) was $27.4K, with a price of $1830.0 per contract. There were 266 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RXRX

8 Health Care Stocks With Whale Alerts In Today's Session

On May 7, the Ninth Circuit <a href="https://www.benzinga.com/topic/ftc" target="_blank" rel="noreferrer noopener">affirmed the decision</a> of the United States District Court for the Northern District of California, FTC versus Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), denying the Commission&#8217;s application for a preliminary injunction to block Microsoft&#8217;s $69 billion acquisition of Activision Blizzard, Inc.  
The Commission has now determined that the public interest is best served by dismissing the administrative litigation <a href="https://www.ftc.gov/legal-library/browse/cases-proceedings/2210077-microsoftactivision-blizzard-matter" target="_blank" rel="noreferrer noopener">in this case</a>.
Also Read: <a href="https://www.benzinga.com/media/25/05/45541908/supermicro-eyes-texas-mississippi-for-ai-server-growth-as-microsoft-amazon-increase-spending" target="_blank" rel="noreferrer noopener">Supermicro Eyes Texas, Mississippi For AI Server Growth As Microsoft, Amazon Increase Spending</a>
Microsoft sold the Xbox gaming console and offered a video game subscription service called Xbox Game Pass and a cloud-based video game streaming service. The agency alleged that the deal would enable Microsoft to suppress competitors to its Xbox gaming consoles and its rapidly growing subscription and cloud-gaming business. The Commission withdrew the matter from adjudication in July 2023 and returned it to adjudication on Sept. 26, 2023. 
Recently, the FTC also dropped a lawsuit against PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) for allegedly <a href="https://www.benzinga.com/government/regulations/25/05/45582935/ftc-scraps-pepsico-price-discrimination-case-in-3-0-vote-marking-major-shift-as-trump-era-leadership-reverses-biden-crackdown" target="_blank" rel="noopener">offering preferential pricing</a> to major retailers like Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>). The case marked broader Biden administration efforts to target price discrimination.
The FTC also paused cases against CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) over pharmacy benefit manager practices, citing commissioner shortages after President Donald Trump&#8216;s personnel changes.
President Trump named FTC Commissioner Andrew Ferguson <a href="https://www.benzinga.com/markets/24/12/42428224/bitcoin-ethereum-dogecoin-mirror-stock-declines-ahead-of-crucial-inflation-data-release-top-analyst-says-buy-the-dip-predicts-275k-btc-target" target="_blank" rel="noopener">his choice</a> for FTC chair last December, replacing Lina Khan. This could potentially reshape the agency&#8217;s approach to tech regulation and antitrust enforcement.
Under Khan&#8217;s leadership, the federal firm has aggressively targeted tech giants, including&nbsp;Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>),&nbsp;Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), and&nbsp;Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).
Price Action: MSFT stock is down 1.06% at $450.31 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45565087/cramer-backs-marvell-again-as-ai-deals-with-amazon-microsoft-fuel-stock-surge" target="_blank" rel="noreferrer noopener">Cramer Backs Marvell Again As AI Deals With Amazon, Microsoft Fuel Stock Surge</a></li>
</ul>
Photo: Shutterstock

Legal

Microsoft Clears Major Hurdle As FTC Ends Effort To Block Activision Merger

The Federal Trade Commission voted 3-0 on Thursday to dismiss a lawsuit against PepsiCo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) that accused the beverage giant of offering preferential pricing to major retailers, marking a significant shift from former President Joe Biden-era corporate scrutiny under the President Donald Trump administration.
What Happened: The FTC dropped the case filed in January&#8217;s final days of the Biden administration, with NBC News <a href="https://www.nbcnews.com/business/business-news/biden-era-pepsi-price-discrimination-suit-dropped-ftc-rcna208635">reporting</a> that Chair Andrew Ferguson criticized it as &#8220;a nakedly political effort to commit this administration to pursuing little more than a hunch that Pepsi had violated the law.&#8221; 
Ferguson, who dissented when the case was originally filed as a commissioner, now leads the agency after President Trump fired two Democratic commissioners in March.
The original lawsuit alleged PepsiCo violated the <a href="https://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-todayhttps://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-today">Robinson-Patman Act</a> by providing unfair pricing advantages to Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) through promotional payments and advertising allowances not extended to competing retailers. 
PepsiCo welcomed the decision, stating it &#8220;has always and will continue to provide all customers with fair, competitive, and non-discriminatory pricing.&#8221; 
See Also: <a href="https://www.benzinga.com/25/05/45581873/top-amd-exec-bets-nearly-1-million-on-stocksignals-confidence-amid-buybacks-easing-tariffs-and-saudi-deal">Top AMD Exec Adds Nearly $1 Million Of The Chipmaker&#8217;s Stock: Signals Confidence Amid Buybacks, Easing Tariffs And Saudi Deal</a> Why It Matters: The case was part of broader Biden administration efforts targeting price discrimination, following a December action against Southern Glazer&#8217;s <a href="https://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-todayhttps://www.benzinga.com/25/01/43063862/whats-going-on-with-pepsico-stock-today">wine and spirits distributor</a>.
The <a href="https://www.benzinga.com/general/health-care/25/04/44627279/ftc-pauses-lawsuit-against-cvs-cigna-unitedhealths-pbms-amid-commissioner-shortage?utm_source=chatgpt.com">FTC also paused separate cases</a> against CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), and UnitedHealth Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) over pharmacy benefit manager practices, citing commissioner shortages after Trump&#8217;s personnel changes. 
Image Via Shutterstock 
Read Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45581845/judge-blocks-trumps-mass-federal-layoffs-citing-need-for-congressional-approval">Judge Blocks Trump&#8217;s Mass Federal Layoffs, Citing Need For Congressional Approval</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Politics

FTC Scraps PepsiCo Price Discrimination Case In 3-0 Vote, Marking Major Shift As Trump-Era Leadership Reverses Biden Crackdown

Macro Economic Events

Market Summary

Economics

FSLR

SEDG

Benzinga Market Summary: Tax Bill Clears The House, Solar Stocks Fall On Plans To Roll Back Clean Energy Credits, Centers For Medicare & Medicaid Services Announce Expansion Of Auditing Efforts For Medicare Advantage Plans

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 50 points on Thursday.
Shares of UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) fell sharply during <a href="https://www.benzinga.com/25/05/45558758/as-unitedhealth-group-lost-an-unthinkable-140-billion-in-market-cap-since-april-analysts-weigh-in-on-the-path-ahead">Thursday's session</a>.
Shares of health insurance stocks traded lower after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.
UnitedHealth has lost nearly $140 billion from its market capitalization following a series of events such as downbeat Q1 results, CEO Andrew Witty stepping down and a potential criminal investigation by the Department of Justice.
UnitedHealth shares declined 2.5% to $295.52 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares dipped 15.1% to $9.05 in pre-market trading after declining around 8% on Wednesday.</li>
<li>Array Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) declined 12.1% to $6.25 in pre-market trading.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) dipped 12.1% to $41.57 in pre-market trading.</li>
<li>Upexi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPXI#NASDAQ">UPXI</a>) fell 9.5% to $11.56 in pre-market trading after gaining over 29% on Wednesday.</li>
<li>Shoals Technologies Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>) dipped 9.1% to $4.28 in pre-market trading.</li>
<li>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) fell 8% to $150.38 in pre-market trading.</li>
<li>Manchester United plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) shares declined 6.9% to $13.54 in pre-market trading.</li>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) slipped 5.2% to $18.81 in pre-market trading. GLJ Research analyst Gordon Johnson, on Wednesday, maintained SolarEdge with a Sell and raised the price target from $3.9 to $6.9.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) fell 2.8% to $60.35 in pre-market trading. Shares of health insurance stocks fell after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.</li>
</ul>
Now Read This:<a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45540545/jim-cramer-recommends-not-buying-mosaic-doesnt-like-this-industrial-stock">Jim Cramer Recommends Not Buying Mosaic, Doesn&#8217;t Like This Industrial Stock</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

ARRY

ENPH

MANU

SHLS

UPXI

UnitedHealth, CVS Health And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

WIIM

ALHC

Shares of health insurance stocks are trading lower after CMS announced a strategy to enhance and accelerate Medicare Advantage audits.

Health care stocks including UnitedHealth Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), Elevance Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) and CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) are tanking in Wednesday's extended trading after the Centers for Medicare &amp; Medicaid Services (CMS) announced a significant expansion of its auditing efforts for <a href="https://www.benzinga.com/content/45529802/unitedhealth-insiders-double-down-is-unh-stock-a-value-play">Medicare Advantage (MA) plans. </a>
The Details: The Centers for Medicare &amp; Medicaid Services said <a href="https://www.cms.gov/newsroom/press-releases/cms-rolls-out-aggressive-strategy-enhance-and-accelerate-medicare-advantage-audits">it will audit</a> all eligible MA contracts for each payment year in newly initiated audits and invest additional resources to expedite the completion of audits in its backlog. 
Read Next: <a href="https://www.benzinga.com/news/large-cap/25/05/45524565/nvidias-1-trillion-comeback-shows-deepseek-no-longer-spooks-wall-street?utm_source=articleShare">Nvidia&#8217;s $1 Trillion Comeback Shows DeepSeek No Longer Spooks Wall Street&nbsp;</a>
"We are committed to crushing fraud, waste and abuse across all federal healthcare programs," said Dr. Mehmet Oz, CMS Administrator.&nbsp;
"While the Administration values the work that Medicare Advantage plans do, it is time CMS faithfully executes its duty to audit these plans and ensure they are billing the government accurately for the coverage they provide to Medicare patients," Dr. Oz added.&nbsp;
The Trump administration will deploy advanced technology, expand the CMS workforce from 40 to 2,000 medical coders and increase its audit volume to all MA plans each year.&nbsp;
CMS also said that its last significant recovery of MA overpayments occurred following the audit of payment year 2007 and estimates suggest MA plans may overbill the government by approximately $17 billion annually.&nbsp;
CMS will now collaborate with the Department of Health and Human Services Office of Inspector General to recover uncollected overpayments identified in past audits.
UNH, ELV, CVS Price Action: After-hours on Wednesday, UnitedHealth stock was down 3.87% at $291.26, Elevance Health stock was down 1.28% at $394.99 and CVS Health shares were down 4.56% at $59.28 at the time of publication.
Read Also:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45506863/trumps-big-beautiful-bill-advances-heres-who-wins-and-loses?utm_source=articleShare">Trump&#8217;s &#8216;Big Beautiful Bill&#8217; Advances: Here&#8217;s Who Wins And Loses&nbsp;</a></li>
</ul>
Image: Shutterstock

Health Care Stocks Like UnitedHealth, CVS Tank On Wednesday: Here's Why

Dividends

Press Releases

CVS Health declares quarterly dividend

CVS Health to hold first quarter 2025 earnings conference call

CVS Health Announces Chief Financial Officer Transition Plan; Appoints Chief Medical Officer

Earnings

CVS HEALTH CORPORATION REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

Glenview Capital Issues Statement on CVS Health

Kirby McInerney LLP Announces Investigation of Claims Against CVS Health Corporation (CVS) on Behalf of Investors

AM Best Affirms Credit Ratings of CVS Health Corporation's Aetna Inc. Subsidiaries

CVS Health celebrates reopening of Hendersonville store destroyed by Hurricane Helene

Synergy CHC Corp. (NASDAQ: SNYR) Taps Beverage Veteran to Drive FOCUSfactor's Drink Expansion – More Stocks Inside

Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion

ALZN

BAOS

CLRB

COST

HTCR

MODV

NAOV

NCEW

SNYR

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

Astrana Health

Aveanna Healthcare Holdings Inc. - Common Stock

Aveanna Healthcare Hldgs

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna Group

CorVel

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

CVS Health

매도 수량

CVS Health (NYSE:CVS) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌